52-week Open Label Safety-Tolerability Study

Conditions

• Schizophrenia

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• LB-102 — DRUG
  LB-102 flexible dosing 50 mg - 100 mg

Study Details

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

Key Dates

Start date

Apr 30, 2026

Status verified

May 2026

Primary completion

Dec 31, 2028

Completion

Apr 30, 2029

Study Design

Enrollment

900 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Other: LB-102
  An open label study

Primary Outcome Measure

Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events. [ Time Frame: 52 weeks ]

Central Contacts

• Anna Eramo, MD
  212-605-0300
  [email protected]
• Branislav Mancevski, MD
  212-605-0300
  [email protected]

Locations (23)

Find similar trials in Chandler, AZ

Related Studies

• Zyprexa® Relprevv™ Patient Care Program
  Enrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
• Database Registry for Neural Network Biomarkers in Psychosis
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
  PHASE4 · Recruiting · Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania
• Bromocriptine for Patients With Schizophrenia and Prediabetes
  PHASE4 · Not Yet Recruiting · VA Pittsburgh Healthcare System · Pittsburgh, Pennsylvania